Alnylam Pharmace. sell Biotechhunter
Start price
31.07.20
/
50%
€125.52
Target price
06.08.20
-
Performance (%)
-3.39%
End price
06.08.20
€121.26
Summary
This prediction ended on 06.08.20 with a price of €121.26. With a performance of -3.39%, the SELL prediction by Biotechhunter was trending in the right direction. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 3.502% | 3.502% | 14.425% | 36.245% |
| iShares Core DAX® | 0.193% | -1.216% | 8.843% | 58.517% |
| iShares Nasdaq 100 | -1.353% | -5.307% | -1.141% | 82.228% |
| iShares Nikkei 225® | -0.426% | 7.319% | 27.580% | 65.208% |
| iShares S&P 500 | -1.008% | -3.400% | -0.222% | 56.665% |